183 related articles for article (PubMed ID: 38004584)
1. Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes.
Gabizon A; Shmeeda H; Draper B; Parente-Pereira A; Maher J; Carrascal-Miniño A; de Rosales RTM; La-Beck NM
Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004584
[TBL] [Abstract][Full Text] [Related]
2. Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy.
Gabizon A; Ohana P; Amitay Y; Gorin J; Tzemach D; Mak L; Shmeeda H
Cancer Drug Resist; 2021; 4(2):463-484. PubMed ID: 35582027
[No Abstract] [Full Text] [Related]
3. Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model.
Islam MR; Patel J; Back PI; Shmeeda H; Adamsky K; Yang H; Alvarez C; Gabizon AA; La-Beck NM
Nanotheranostics; 2022; 6(4):451-464. PubMed ID: 36105861
[No Abstract] [Full Text] [Related]
4. Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer.
Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Stern ST; Barenholz Y; Gabizon A
J Drug Target; 2016 Nov; 24(9):878-889. PubMed ID: 27187807
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
[TBL] [Abstract][Full Text] [Related]
6. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
7. Recent Preclinical and Clinical Progress in Liposomal Doxorubicin.
Aloss K; Hamar P
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986754
[TBL] [Abstract][Full Text] [Related]
8. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
9. Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model.
Islam MR; Patel J; Back PI; Shmeeda H; Kallem RR; Shudde C; Markiewski M; Putnam WC; Gabizon AA; La-Beck NM
Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759709
[TBL] [Abstract][Full Text] [Related]
10. Novel Core-Interlayer-Shell DOX/ZnPc Co-loaded MSNs@ pH-Sensitive CaP@PEGylated Liposome for Enhanced Synergetic Chemo-Photodynamic Therapy.
Ma J; Wu H; Li Y; Liu Z; Liu G; Guo Y; Hou Z; Zhao Q; Chen D; Zhu X
Pharm Res; 2018 Feb; 35(3):57. PubMed ID: 29423532
[TBL] [Abstract][Full Text] [Related]
11. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment.
Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT
Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348
[TBL] [Abstract][Full Text] [Related]
12. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
13. A liposomal formulation of simvastatin and doxorubicin for improved cardioprotective and anti-cancer effect.
Bjørnstad R; Reiten IN; Knudsen KS; Schjøtt J; Herfindal L
Int J Pharm; 2022 Dec; 629():122379. PubMed ID: 36370997
[TBL] [Abstract][Full Text] [Related]
14. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy.
Thomas E; Menon JU; Owen J; Skaripa-Koukelli I; Wallington S; Gray M; Mannaris C; Kersemans V; Allen D; Kinchesh P; Smart S; Carlisle R; Vallis KA
Theranostics; 2019; 9(19):5595-5609. PubMed ID: 31534505
[TBL] [Abstract][Full Text] [Related]
16. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
17. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
[TBL] [Abstract][Full Text] [Related]
18. Self-assembly of porphyrin-grafted lipid into nanoparticles encapsulating doxorubicin for synergistic chemo-photodynamic therapy and fluorescence imaging.
Hameed S; Bhattarai P; Liang X; Zhang N; Xu Y; Chen M; Dai Z
Theranostics; 2018; 8(19):5501-5518. PubMed ID: 30555560
[TBL] [Abstract][Full Text] [Related]
19. Ratiometric co-delivery of doxorubicin and paclitaxel prodrug by remote-loading liposomes for the treatment of triple-negative breast cancer.
Wang Y; Chen L; Zhang Z; Liu W; Li L
Drug Deliv Transl Res; 2022 Oct; 12(10):2537-2549. PubMed ID: 35043372
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats.
Wang JC; Liu XY; Lu WL; Chang A; Zhang Q; Goh BC; Lee HS
Eur J Pharm Biopharm; 2006 Jan; 62(1):44-51. PubMed ID: 16126379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
